Analysts See $-0.42 EPS for ObsEva SA (OBSV)

April 14, 2018 - By Vivian Currie

Analysts expect ObsEva SA (NASDAQ:OBSV) to report $-0.42 EPS on May, 17.They anticipate $0.16 EPS change or 27.59 % from last quarter’s $-0.58 EPS. After having $-0.48 EPS previously, ObsEva SA’s analysts see -12.50 % EPS growth. The stock decreased 3.29% or $0.45 during the last trading session, reaching $13.24. About 3,671 shares traded. ObsEva SA (NASDAQ:OBSV) has risen 20.97% since April 14, 2017 and is uptrending. It has outperformed by 9.42% the S&P500.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company has market cap of $491.62 million. The firm intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It currently has negative earnings. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy.

ObsEva SA (NASDAQ:OBSV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.